Phase 2 randomized controlled trials evaluating the safety of CTLA-4-targeted agents [2,3,4] or (PD)-1 and (PD-L1)-targeted agents in patients with advanced melanoma did not suggest an increased risk of infection. This evidence concerns the gene CD274 and melanoma.